TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT07220993

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing CD7.CAR/28zeta T Cells for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

Who can join (key eligibility)

  • Lymphoma came back or did not respond to prior treatment
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

CD7.CAR/28zeta T Cells (GENETIC): Fourdose levels will be evaluated: Dose level one: 1×10\^7 cells/m\^2 Dose level two: 3×10\^7 cells/m\^2 Dose level three: 5x10\^7 cells/m\^2 Dose level four: 1×10\^8 cells/m\^2

Drugs / treatments
CD7.CAR/28zeta T Cells
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

NCT07220993

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing CD7.CAR/28zeta T Cells for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

Who can join

  • Lymphoma came back or did not respond to prior treatment
  • See full trial listing for complete eligibility

What's being tested

CD7.CAR/28zeta T Cells (GENETIC): Fourdose levels will be evaluated: Dose level one: 1×10\^7 cells/m\^2 Dose level two: 3×10\^7 cells/m\^2 Dose level three: 5x10\^7 cells/m\^2 Dose level four: 1×10\^8 cells/m\^2

Drugs / treatments: CD7.CAR/28zeta T Cells

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 27 patients

Primary endpoint: Dose limiting toxicity rate

Ages: — to 75 Years

Start date: 2026-05-12 | Est. completion: 2043-12

Locations

2 US sites · 2 total

Texas

Contact

Rayne Rouce | rhrouce@txch.org | 832-824-4716

Sponsor: Baylor College of Medicine (OTHER)

Tags

AITL/TFH · ALCL · ATLL · CTCL · EATL · ENKTL · MEITL · T-PLL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07220993

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.